The FDA is signaling greater flexibility in approving certain new drugs based on a single adequate and well-controlled clinical trial, rather than the historical expectation of two pivotal studies.^1-3

Under current law, the FDA has long retained discretion to approve drugs based on “substantial evidence” of effectiveness, which can be derived from one robust trial with confirmatory evidence, depending on context.¹ However, in practice, sponsors have frequently conducted two pivotal studies to mitigate regulatory risk. The renewed emphasis on single-study approvals may alter development strategies, capital allocation, and launch sequencing across therapeutic categories.

“Going forward, the FDA’s default position is that one adequate and well-controlled study, combined with confirmatory evidence, will serve as the basis of marketing authorization of novel products,” wrote Vinay Prasad, MD, MPH, and Martin Makary, MD, MPH, the FDA’s vaccine chief and commissioner respectively wrote in a recent New England Journal of Medicine piece.¹ “The FDA will carefully examine all aspects of study design with particular focus on controls, end points, effect size, and statistical protocols. Without examination of the quality of a study, two trials may even provide a false assurance. The FDA expects a surge in drug development in response to our initiative.”

For pharmaceutical supply chain and commercial planning teams, the implications extend beyond regulatory policy, potentially affecting manufacturing ramp-up timelines, clinical supply forecasting, and launch readiness.

What is changing in FDA’s evidentiary expectations?

The NEJM analysis¹ notes that FDA approval standards have historically allowed flexibility when a single trial is deemed sufficiently persuasive, particularly if supported by confirmatory evidence such as mechanistic data, related trials, or compelling clinical endpoints.¹ The article emphasizes that the statutory standard—“substantial evidence”—does not explicitly require two trials.

Recent reporting indicates the agency may more openly rely on this interpretation, potentially reducing the routine expectation of two large, replicate Phase III trials in certain circumstances. According to coverage in The American Journal of Managed Care and Pharmaceutical Executive, FDA leadership has indicated that requiring only one adequate and well-controlled study in appropriate cases could speed patient access while maintaining evidentiary rigor.^2,3

However, the scope of application remains unclear. The policy does not eliminate the need for robust data, and the FDA continues to evaluate benefit-risk profiles, endpoint validity, statistical strength, and safety databases on a case-by-case basis.¹

What are the potential development and investment impacts?

Reducing reliance on duplicate Phase III trials could shorten development timelines and decrease development costs in certain scenarios. Clinical trials represent a major component of drug development spending, and eliminating a second large-scale study could materially alter capital requirements and risk models.

For sponsors, a single-study pathway may encourage earlier submission strategies or adaptive trial designs. It may also influence portfolio prioritization, particularly in therapeutic areas where patient populations are limited or where unmet need is high.

At the same time, some stakeholders have raised concerns about evidentiary robustness. The NEJM analysis underscores that single-study approvals must still meet statutory thresholds and that reliance on less confirmatory data could heighten post-marketing surveillance demands.¹ Accelerated or flexible approval models could therefore shift some evidentiary generation into the post-approval period.

How could this shift affect pharma supply chain planning?

From a Pharmaceutical Commerce perspective, earlier approvals based on one pivotal trial could compress commercial launch timelines. Manufacturing scale-up, technology transfer, packaging validation, and distribution planning may need to align more tightly with clinical milestones.

Shorter development cycles can reduce long-term forecasting visibility for contract manufacturing organizations and active pharmaceutical ingredient suppliers. Conversely, faster approvals may require earlier investment in commercial-scale production before full replication of efficacy data, potentially increasing financial exposure.

The policy shift could also affect clinical supply chains. If sponsors pursue single pivotal trials more frequently, there may be fewer late-stage clinical manufacturing campaigns but greater emphasis on ensuring that pivotal batches are representative of commercial product.

Downstream, payers and health systems may adjust evidence review frameworks if approvals rely on fewer trials. That dynamic could influence uptake curves, reimbursement negotiations, and inventory planning during early launch phases.

What questions remain?

Although FDA has the authority to approve drugs based on one adequate and well-controlled study, observers note that implementation details will be critical. The agency has not published a formal rule eliminating the two-study expectation, and regulatory discretion will likely continue to vary by therapeutic area and evidentiary strength.

For life sciences companies and supply chain stakeholders, monitoring how frequently single-study approvals are granted, and in which disease categories, will be essential. The balance between speed, evidentiary confidence, and post-market obligations may shape both regulatory strategy and operational execution in the coming years.

References

1. Prasad V, Makary MA. One pivotal trial, the new default option for FDA approval—ending the two-trial dogma. N Engl J Med. 2026;394(8):815-817. doi:10.1056/NEJMsb2517623 https://www.nejm.org/doi/full/10.1056/NEJMsb2517623

2. Bonavitacola J. FDA Will Require Only 1 Study to Approve New Drugs, Speeding Up Process. The American Journal of Managed Care. Published February, 19 2026. Accessed February 19, 2026. https://www.ajmc.com/view/fda-will-require-only-1-study-to-approve-new-drugs-speeding-up-process

3. Jacobus N. FDA removes two-study requirement from new drug approval process: Report. Pharmaceutical Executive. Published February 19, 2026. Accessed February 19, 2026. https://www.pharmexec.com/view/fda-removes-two-study-requirement-new-drug-approval-process-report